SeaStar Medical (ICU) vs Neuphoria Therapeutics (NEUP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
SeaStar Medical (ICU) has outperformed Neuphoria Therapeutics (NEUP) over the past year, losing 47.0% versus a loss of 81.8%. SeaStar Medical is the larger company by market cap ($18.4 million vs $18.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ICU | NEUP |
|---|---|---|
| Share price | $3.49 | $3.35 |
| Market cap | $18.36M | $18.13M |
| 1-day change | -6.18% | -2.05% |
| YTD return | +45.42% | -13.66% |
| 1-year return | -47.04% | -81.76% |
| 5-year return | -99.86% | — |
| EPS (TTM) | $-2.97 | $-2.99 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.35 | $19.21 |
| 52-week low | $2.07 | $3.19 |
| Distance from 52-week high | -52.52% | -82.56% |
| Analyst consensus | none | none |
| Avg. price target upside | +186.53% | — |
| Average volume | 99.80K | 161.66K |
| Shares outstanding | 5.26M | 5.41M |
| Employees | 18 | 1 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ICU has outperformed NEUP by 34.7 percentage points over the past year.
About SeaStar Medical
ICU stock →SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis.
Healthcare · Biotechnology · 18 employees
About Neuphoria Therapeutics
NEUP stock →Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder.
Healthcare · Biotechnology · 1 employees
ICU vs NEUP FAQ
Which is bigger, SeaStar Medical or Neuphoria Therapeutics?
SeaStar Medical (ICU) is larger, with a market capitalization of $18.36M compared with $18.13M for Neuphoria Therapeutics (NEUP).
Which stock has performed better over the past year, ICU or NEUP?
ICU returned -47.04% over the past 12 months, compared with -81.76% for NEUP (price return, excluding dividends). Past performance does not predict future results.
Are SeaStar Medical and Neuphoria Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.